Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics Corp. is set to present promising pre-clinical data on its innovative IL-2 Superkines, MDNA11, at two major oncology conferences. These presentations could attract investor interest as they highlight advancements in treating aggressive cancers like glioblastoma and breast cancer.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
